Prevalence of Human T-Lymphotropic Virus Type III Antibodies Among Patients in Dialysis Programs at a University Hospital
- ALLAN J. MORRISON, Jr., M.D., M.S.;
- CAROL V. FREER, M.D.;
- C. LYNN POOLE, R.N.P.;
- DANA O. JOHNSTON, R.N.P.;
- FREDERIC WESTERVELT, Jr., M.D.;
- DAVID E. NORMANSELL, Ph.D.; and
- RICHARD P. WENZEL, M.D.
Excerpt
More than 13 000 cases of the acquired immunodeficiency syndrome (AIDS) have been reported. The identification of the human T-lymphotropic virus type III (HTLV-III) as the causative agent has led to an increased understanding of the likely modes of transmission as well as the identification of persons at risk for infection. Currently, about 80 000 patients require regular dialysis in the United States (1). Patients requiring such dialysis would appear to be at high risk for infection with HTLV-III because of their having received multiple transfusions before the initiation of nationwide screening of blood products for HTLV-III antibody (2, 3).
This 100-word excerpt has been provided in the absence of an abstract.
Acknowledgments
ACKNOWLEDGMENTS: Grant support: in part by grant T32-AI074046 from the National Institutes of Health.
Article and Author Information
-
▸Requests for reprints should be addressed to Allan J. Morrison, Jr., M.D., M.S.; 3299 Woodburn Road, Suite 220; Annandale, VA 22003.
Most Read
